AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech
Category: #health  By Pankaj Singh  Date: 2019-10-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech

Owing to widescale tobacco use, the world is seeing an increased number of cancer and vascular diseases. India alone registers more than 10 million cases of peripheral artery disease on an annual basis. Technology and healthcare enterprises are increasingly innovating novel, non-invasive medical devices to treat peripheral artery disease.

AngioDynamics, Inc., a renowned innovative, non-invasive medical device provider for oncology, vascular access and peripheral vascular disease, reportedly announced that it acquired Israel-based early stage medical device company, Eximo Medical, Ltd., as well as its proprietary 355nm Laser Atherectomy technology for $46 million.

The $46 million would be given in upfront consideration with approximately $20 million worth of contingent consideration subject to completion of certain revenue and technical milestones. AngioDynamics would be funding the transaction exclusively using cash on hand.

The acquisition further expands AngioDynamics’ current product portfolio of Vascular Interventions and Therapies (VIT) through Eximo’s laser technology, which boasts of 510(k) clearance for treating Peripheral Artery Disease (PAD). Israeli company’s technology greatly compliments AngioDynamics’ industry leading venous insufficiency and thrombus management technologies.

The President and CEO of AngioDynamics, Jim Clemmer stated that the takeover brings a remarkable technology to the company’s portfolio, helping it change the way caregivers provide treatments to PAD patients. Clemmer added that the industry is ripe for a disruption, the overall level of safety, precision, and efficiency facilitated by this technology to physicians creates a significantly differentiated alternative to conventional atherectomy devices.

Distinguished from conventional medical devices, the laser atherectomy technology of Eximo is the only platform capable of facilitating high-powered, short pulsed laser in a 355nm wavelength without having to compromise on its fiber optic cable integrity during the atherectomy procedures.

The technology efficiently addresses the perforation risk through tissue selectivity, addressing the risk of embolization for the patient using the availability of aspiration. It is also indicated to treat In-Stent Restenosis (ISR), a gradual, re-narrowing of the patient’s artery after the blockages have been treated with a stent previously.

Moreover, the Eximo laser technology further advances patient treatment alternatives and care by addressing a plethora of PAD lesion types both below- and above-the-knee.

AngioDynamics management was scheduled to discuss the acquisition transaction during the company’s FY2020 First Quarter Financial Results Conference Call on October 3, 2019.

Source credit: https://www.businesswire.com/news/home/20191003005184/en/AngioDynamics-Acquires-Eximo-Medical-Ltd.-Innovative-355nm

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

CoSara receives Indian regulatory authorization for its five IVDs
CoSara receives Indian regulatory authorization for its five IVDs
By Pankaj Singh

Co-Diagnostics, a renowned US-based molecular diagnostics company, having a patented, unique platform to develop diagnostics tests reportedly announced that CoSara Diagnostics, the company’s JV for production, has received regulatory clearance ...

U.S. government could issue new rules to block shipments to Huawei
U.S. government could issue new rules to block shipments to Huawei
By Pankaj Singh

  Trump administration had issued 75 licenses to allow Huawei suppliers to resume sales U.S. Commerce Department and other authorities focused on utilizing De minimis Rule The U.S. government is reportedly considering new policies to restr...

Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
By Pankaj Singh

Cinda Biopharmaceutical, a startup that focuses on treating autoimmune and metabolic diseases, has recently announced the completion of its Phase I clinical study of human epidermal growth factor receptor-2 (HER2) and antibodies against programmed de...